Onconetix (ONCO) investor relations material

Executive summary

• Special meeting scheduled for April 30, 2026, to vote on two key proposals: a reverse stock split amendment and potential adjournment to solicit more proxies if needed.

• The Board unanimously recommends voting in favor of both proposals, citing the need to maintain Nasdaq listing compliance.

• Record date for voting eligibility is March 13, 2026, with 3,473,352 shares of common stock outstanding.

• Proxy solicitation is managed by Alliance Advisors, with an estimated fee of $21,000 plus expenses.

Voting matters and shareholder proposals

• Proposal 1: Grant Board authority to amend the Charter for one or more reverse stock splits at ratios between 1-for-2 and 1-for-10, not exceeding 1-for-100 in aggregate, within one year of the meeting.

• Proposal 2: Approve adjournment of the meeting if more time is needed to solicit proxies for Proposal 1.

• Both proposals require a majority of votes cast by stockholders present or represented by proxy.

• All proposals are considered routine, allowing brokers discretionary voting authority.

Board of directors and corporate governance

• The Board retains discretion to implement or abandon any reverse stock split within the approved range and timeframe.

• No changes to the rights or preferences of existing stockholders, except for treatment of fractional shares.